Tumour expression of growth factor receptors of the HER family makes it possible to perform innovative therapeutic targeting as demonstrated by the development of clinically active drugs such as herceptin(®), cetuximab and EGFR tyrosine kinase inhibitors (Gross et al, 2004). Here, EGFR is linked to neoplasm.